CL2008001766A1 - Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis. - Google Patents
Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis.Info
- Publication number
- CL2008001766A1 CL2008001766A1 CL2008001766A CL2008001766A CL2008001766A1 CL 2008001766 A1 CL2008001766 A1 CL 2008001766A1 CL 2008001766 A CL2008001766 A CL 2008001766A CL 2008001766 A CL2008001766 A CL 2008001766A CL 2008001766 A1 CL2008001766 A1 CL 2008001766A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- thioxanthin
- cardio
- bronchitis
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
Abstract
Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; proceso de preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de enfermedades, tales como, epoc, bronquitis, insuficiencia cardiaca, trastornos ateroscleróticos cardio y cerebrovasculares, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94367107P | 2007-06-13 | 2007-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001766A1 true CL2008001766A1 (es) | 2008-12-19 |
Family
ID=39744966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001766A CL2008001766A1 (es) | 2007-06-13 | 2008-06-13 | Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080312311A1 (es) |
EP (1) | EP2158202A1 (es) |
JP (1) | JP2010529185A (es) |
KR (1) | KR20100020002A (es) |
CN (1) | CN101679435A (es) |
AR (1) | AR066936A1 (es) |
AU (1) | AU2008263582A1 (es) |
BR (1) | BRPI0812480A2 (es) |
CA (1) | CA2690468A1 (es) |
CL (1) | CL2008001766A1 (es) |
CO (1) | CO6251290A2 (es) |
EC (1) | ECSP109874A (es) |
IL (1) | IL202281A0 (es) |
MX (1) | MX2009013126A (es) |
PE (1) | PE20090367A1 (es) |
RU (1) | RU2010100484A (es) |
TW (1) | TW200916096A (es) |
UY (1) | UY31139A1 (es) |
WO (1) | WO2008152420A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
WO2010068171A1 (en) * | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one |
US11246870B2 (en) * | 2017-07-17 | 2022-02-15 | Astrazenca Ab | MPO inhibitors for use in medicine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
UY30267A1 (es) * | 2006-04-13 | 2007-11-30 | Astrazeneca Ab | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones |
WO2007120097A1 (en) * | 2006-04-13 | 2007-10-25 | Astrazeneca Ab | Thioxanthine derivatives and their use as inhibitors of mpo |
-
2008
- 2008-06-09 AR ARP080102458A patent/AR066936A1/es unknown
- 2008-06-11 CN CN200880020106A patent/CN101679435A/zh active Pending
- 2008-06-11 KR KR1020097025947A patent/KR20100020002A/ko not_active Application Discontinuation
- 2008-06-11 WO PCT/GB2008/050433 patent/WO2008152420A1/en active Application Filing
- 2008-06-11 AU AU2008263582A patent/AU2008263582A1/en not_active Abandoned
- 2008-06-11 CA CA2690468A patent/CA2690468A1/en not_active Abandoned
- 2008-06-11 MX MX2009013126A patent/MX2009013126A/es not_active Application Discontinuation
- 2008-06-11 JP JP2010511729A patent/JP2010529185A/ja active Pending
- 2008-06-11 BR BRPI0812480A patent/BRPI0812480A2/pt not_active IP Right Cessation
- 2008-06-11 RU RU2010100484/04A patent/RU2010100484A/ru not_active Application Discontinuation
- 2008-06-11 UY UY31139A patent/UY31139A1/es unknown
- 2008-06-11 EP EP08762543A patent/EP2158202A1/en not_active Withdrawn
- 2008-06-12 TW TW097121960A patent/TW200916096A/zh unknown
- 2008-06-12 US US12/137,583 patent/US20080312311A1/en not_active Abandoned
- 2008-06-13 PE PE2008001012A patent/PE20090367A1/es not_active Application Discontinuation
- 2008-06-13 CL CL2008001766A patent/CL2008001766A1/es unknown
-
2009
- 2009-11-23 IL IL202281A patent/IL202281A0/en unknown
- 2009-12-09 CO CO09140840A patent/CO6251290A2/es not_active Application Discontinuation
-
2010
- 2010-01-13 EC EC2010009874A patent/ECSP109874A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008263582A1 (en) | 2008-12-18 |
RU2010100484A (ru) | 2011-07-20 |
IL202281A0 (en) | 2010-06-16 |
BRPI0812480A2 (pt) | 2017-05-23 |
JP2010529185A (ja) | 2010-08-26 |
ECSP109874A (es) | 2010-02-26 |
UY31139A1 (es) | 2009-01-30 |
PE20090367A1 (es) | 2009-04-15 |
AR066936A1 (es) | 2009-09-23 |
KR20100020002A (ko) | 2010-02-19 |
CA2690468A1 (en) | 2008-12-18 |
CN101679435A (zh) | 2010-03-24 |
CO6251290A2 (es) | 2011-02-21 |
EP2158202A1 (en) | 2010-03-03 |
TW200916096A (en) | 2009-04-16 |
MX2009013126A (es) | 2010-01-15 |
WO2008152420A1 (en) | 2008-12-18 |
US20080312311A1 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
CL2012003178A1 (es) | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. | |
SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
ECSP12012125A (es) | Ariltriazolonas ligadas a bisarilo y su uso | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
NI200700296A (es) | Imidazoquinolinas como inhibidores de cinasa de lipido | |
UY33480A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento. | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2008000531A1 (es) | Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda | |
CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
CL2008000307A1 (es) | Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc. | |
GT200500360A (es) | Compuestos organicos | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
UY31922A (es) | Compuestos | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
DOP2011000107A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales | |
UY32052A (es) | 5-aminopirazoles sustituidos y uso de los mismos | |
CL2013002129A1 (es) | Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras. | |
UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
CL2013000502A1 (es) | Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina. |